Pharmaceutical sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd Clinical Trials
Studies where Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 24Generalized Myasthenia Gravis
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of SHR-2173 compared to placebo as an add-on…
- Trial name
- NCT07622342
- Testing
- SHR-2173 injection
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Systemic Lupus Erythematosus
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
This study is a randomized, double-blind, multi-center, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in adult participants with active Systemic Lupus Erythematosus (SLE), including a…
- Trial name
- NCT07299422
- Testing
- SHR-2173 Injection
- Where
- 2 sites in China
- Volunteers
- 248 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Moderate-to-severe Inflammatory Bowel Disease
A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease
This Phase I first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-7590 via subcutaneous or intravenous administration in Chinese healthy participants and patients with…
- Trial name
- NCT07758101
- Testing
- SHR-7590
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Body Weight Management
A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity
This study is a single-center, randomized, double-blind, dose-escalation, placebo-parallel-controlled Phase I clinical trial. The primary objective is to evaluate the safety and tolerability of a single subcutaneous injection of…
- Trial name
- NCT07826364
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Adolescents With Moderate-to-severe Atopic Dermatitis
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07309055
- Testing
- SHR-1819 Injection
- Where
- 2 sites in China
- Volunteers
- 201 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Cutaneous Lupus Erythematosus(CLE)
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
- Trial name
- NCT07749651
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Psoriasis
Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis
This study is a randomized, double-blind, multi-center, parallel, phase II clinical trial, aiming to evaluate the efficacy and safety of SHR-1139 injection for adult patients with psoriasis.
- Trial name
- NCT07719530
- Testing
- The SHR-1139 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
COPD
A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The study is being conducted to evaluate the efficacy and safety of HRS-9821 for patients with COPD, and to explore the reasonable dosage of HRS-9821 for patients with COPD.
- Trial name
- NCT07640451
- Testing
- HRS-9821 Inhalation Suspension
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Plaque Psoriasis
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis
This study is a randomized, double-blind, multicenter, dose-parallel-controlled phase II clinical trial. The study consists of three stages: a 4-week screening period, a 52-week treatment period, and a 12-week follow-up period.
- Trial name
- NCT07758075
- Testing
- SHR-1139, SHR-1139 and SHR-1139 pleacebo
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
COPD
A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation administered in a single dose in healthy individuals and multiple doses in patients with COPD。
- Trial name
- NCT07567872
- Testing
- HRS-9821 Powder for Inhalation
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd